Pharmacokinetics of clarithromycin and concentrations in body fluids and bronchoalveolar cells of foals

American Journal of Veterinary Research

Volumn 67, Issue 10, 2006, Pages 1681-1686

  Womble, Ariel Y ^a   Giguère, Steeve ^a   Lee, Elise A ^a   Vickroy, Thomas W ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DRUG METABOLITE; ROXITHROMYCIN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BODY FLUID; CEREBROSPINAL FLUID; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORSE; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; MALE; NONHUMAN; PERITONEAL FLUID; SERUM; STEADY STATE; SYNOVIAL FLUID; URINE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASCITIC FLUID; BRONCHOALVEOLAR LAVAGE FLUID; CLARITHROMYCIN; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HORSES; INJECTIONS, INTRAVENOUS; MALE; SYNOVIAL FLUID; TISSUE DISTRIBUTION;

ANIMALIA; RHODOCOCCUS EQUI;

EID: 33750219295     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.10.1681     Document Type: Article

References (36)

1. Conte JE, Golden JA, Duncan S, et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995;39:334-338.
2. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;37:385-398.
3. Ferrero JL, Bopp BA, Marsh KC, et al. Metabolism and disposition of clarithromycin in man. Drug Metab Dispos 1990;18:441-446.
4. Fernandes PB, Ramer N, Rode RA, et al. Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin. Eur J Clin Microbiol Infect Dis 1988;7:73-76.
5. Martin SJ, Garvin CG, McBurney CR, et al. The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001;47:581-587.
6. Hillidge CJ. Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia. Vet Microbiol 1987;14:337-342.
7. Jacks S, Giguère S, Nguyen A. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin and 20 other antimicrobials. Antimicrob Agents Chemother 2003;47:1742-1745.
8. Giguère S, Jacks S, Roberts GD, et al. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia. J Vet Intern Med 2004;18:568-573.
9. Jacks S, Giguère S, Gronwall RR, et al. Disposition of oral clarithromycin in foals. J Vet Pharmacol Ther 2002;25:359-362.
10. Drusano GL. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy 2005;25:150S-158S.
11. Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 1992;36:1171-1175.
12. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986;60:532-538.
13. Conte JE, Golden J, Duncan S, et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996;40:1617-1622.
14. Jacks S, Giguère S, Gronwall PR, et al. Pharmacokinetics of azithromycin and concentration in body fluids and bronchoalveolar cells in foals. Am J Vet Res 2001;62:1870-1875.
15. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory In: Gibaldi M, Perrier D, eds. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982;409-417.
16. Bedos JP, Azoulay-Dupuis E, Vallee E, et al. Individual efficacy of clarithromycin (A-56268) and its major human metabolite 14-hydroxy clarithromycin (A-62671) in experimental pneumococcal pneumonia in the mouse. J Antimicrob Chemother 1992;29:677-685.
17. Wimsatt JH, Johnson J, Mangone BA, et al. Clarithromycin pharmacokinetics in the desert tortoise (Gopherus agassizii). J Zoo Wildl Med 1999;30:36-43.
18. Gan VN, Chu SY, Kusmiesz HT, et al. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother 1992;36:2478-2480.
19. Chu SY, Deaton R, Cavanaugh J. Absolute bioavailability of clarithromycin after oral administration in humans. Antimicrob Agents Chemother 1992;36:1147-1150.
20. Vilmanyi E, Kung K, Riond JL, et al. Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles. J Small Anim Pract 1996;37:535-539.
21. Davis JL, Gardner SY, Jones SL, et al. Pharmacokinetics of azithromycin in foals after i.v. and oral dose and disposition into phagocytes. J Vet Pharmacol Ther 2002;25:99-104.
22. Lakritz J, Wilson WD, Marsh AE, et al. Effects of prior feeding on pharmacokinetics and estimated bioavailability after oral administration of a single dose of microencapsulated erythromycin base in healthy foals. Am J Vet Res 2000;61:1011-1015.
23. Lakritz J, Wilson WD, Marsh AE, et al. Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals. Am J Vet Res 2000;61:914-919.
24. Prescott JF, Hoover DJ, Dohoo IR. Pharmacokinetics of erythromycin in foals and in adult horses. J Vet Pharmacol Ther 1983;6:67-73.
25. Lakritz J, Wilson WD, Mihalyi JE. Comparison of microbiologic and high-performance liquid chromatography assays to determine plasma concentrations, pharmacokinetics, and bioavailability of erythromycin base in plasma of foals after intravenous or intragastric administration. Am J Vet Res 1999;60:414-419.
26. Craig WA. Postantibiotic effects and the dosing of macrolides, azalides, and streptogramins. In: Zinner SH, Young LS, Acar JF, et al, eds. Expanding indications for the new macrolides, azalides, and streptogramins. 3rd ed. New York: Marcel Dekker Inc, 1997;27-38.
27. Tessier PR, Kim MK, Zhou W, et al. Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 2002;46:1425-1434.
28. Fietta A, Merlini C, Gialdroni GG. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J Chemother 1997;9:23-31.
29. Mandell GL, Coleman E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001;45:1794-1798.
30. Retsema JA, Bergeron JM, Girard D, et al. Preferential concentration of azithromycin in an infected mouse thigh model. J Antimicrob Chemother 1993;31(suppl E):5-16.
31. Rodvold KA, Gotfried MH, Danziger LH, et al. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997;41:1399-1402.
32. Maglio D, Capitano B, Banevicius MA, et al. Differential efficacy of clarithromycin in lung versus thigh infection models. Chemotherapy 2004;50:63-66.
33. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-2379.
34. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999;74:613-634.
35. Stratton-Phelps M, Wilson WD, Gardner IA. Risk of adverse effects in pneumonic foals treated with erythromycin versus other antibiotics: 143 cases (1986-1996). J Am Vet Med Assoc 2000;217:68-73.
36. Anderson G, Esmonde TS, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia. J Antimicrob Chemother 1991;27(suppl A):117-124.